{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-071512","form_type":"8-K","ticker":"CARL","cik":"0001794546","company_name":"CARLSMED, INC.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.199532+00:00","generated_at":"2026-05-16T00:24:53.603373+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Carlsmed Q4 revenue $15.2M (+61% YoY); FY rev $50.5M (+86%); guides FY2026 $70-75M","bullets":["Q4 rev $15.2M (+61% YoY), FY rev $50.5M (+86% YoY). Gross margin 76.5% Q4, 75.3% FY.","Net loss Q4 ($8.6M), FY ($29.6M); adj. EBITDA loss Q4 ($8.4M), FY ($28.4M).","Cash, cash equivalents, restricted cash, and ST investments $109.9M at Dec 31, 2025.","FY2026 revenue guidance $70-75M, representing ~44% growth at midpoint over 2025.","2-year data showed 74% reduction in revision rates for aprevo® lumbar vs non-aprevo."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-071512","json":"https://secwatch.observer/filing/0001193125-26-071512.json","markdown":"https://secwatch.observer/filing/0001193125-26-071512.md","text":"https://secwatch.observer/filing/0001193125-26-071512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1794546/000119312526071512/0001193125-26-071512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1794546/000119312526071512/carl-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:24:53.603373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}